In another study, STAT3 activation correlated with dasatinib resistance in pancreatic cancer cells [135], while dual inhibition of STAT3 and SRC resulted in significantly smaller PDAC tumors in mice compared to monotherapy-treated groups [204]. This evidence concerns the gene SRC and familial pancreatic carcinoma.